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(p < 0.05). GIQLI total score and symptoms subscale discrimi-
nated among most severity levels (p < 0.05). CONCLUSIONS:
The GSRS and GIQLI demonstrated adequate reliability, and
outperformed generic instruments on discriminant validity. Both
instruments can be used to investigate effects on PRO’s related
to GI complications due to immunosuppressant therapies.
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OBJECTIVES: Irritable bowel syndrome (IBS) is a chronic and
episodic disorder characterized by abdominal pain and altered
bowel habits. Its impact on generic and disease-speciﬁc quality
of life and self-perceived health status is rarely assessed in The
Netherlands. This study assessed the impact of IBS on health-
related quality of life (HRQoL). METHODS: Patients using
mebeverine, identiﬁed at community pharmacies, were adminis-
tered a questionnaire regarding ROME-II-criteria to conﬁrm the
IBS diagnosis, abdominal complaints, use of medical resources,
abdominal pain and discomfort (IGA-P VAS with 0 = no pain
and 1 = very severe pain), patient self-perceived health status
(VAS with 0 = worst imaginable health state i.e. death and 1 =
best possible health state, and SF-6D), generic HRQoL (SF-36)
and IBS-speciﬁc HRQol (IBSQoL). SF-36 outcomes were com-
pared to a random sample of the Dutch population and other
Dutch patients suffering from chronic diseases. The association
between HRQol and severity of disease (IGA-P) was assessed.
RESULTS: A total of 212 completed questionnaires were
received. A total of 169 patients met the ROME-II-criteria for
diagnosis of IBS. Of those, 18% suffered from IBS with diarrhea
predominance, 19% from IBS with constipation predominance
and 51% reported an alternating stool pattern. Severe abdomi-
nal pain (IGA-P >60mm on a 100mm VAS) was reported by
65%. Sufﬁcient differences between the IBS-population and the
Dutch population were measured for all dimensions of the SF-
36. SF-36 and IBSQoL outcomes were associated with disease
severity. Patients regarded their health state as low: 0.62 (0.2)
on a VAS and 0.66 (0.1) using the SF-6D algorithm. CONCLU-
SIONS: IBS has a signiﬁcant impact on all dimensions of HRQol.
Our ﬁndings are consistent with other studies. There is an unmet
medical need in patients suffering from IBS in The Netherlands.
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OBJECTIVES: Primary objective of the study was to determine
the effect of tegaserod six mg b.i.d. on quality of life (QoL) of
women with IBS-C (deﬁned by Rome II criteria). The secondary
objective was to determine the efﬁcacy of tegaserod in this pop-
ulation. METHODS: This was a prospective open-label, multi-
center study in South Africa with gastroenterologist, surgeon and
gynaecologist enrollers. The study comprised a two-week treat-
ment-free baseline period (rescue medication permitted) followed
by a four-week treatment period (rescue medication permitted
for patients not experiencing adequate relief with tegaserod). The
IBS-QoL questionnaire, a validated instrument that assesses the
impact of IBS and treatment of the condition, was completed at
study entry, after the baseline period and at study end. It con-
sists of seven domains: dysphoria, interference with activity,
body image, health worry, food avoidance, social reaction and
sexual relationship. Patients also kept a diary and recorded IBS
symptoms daily and overall symptom relief weekly. RESULTS:
In total, 242 patients from 36 centers were recruited; 210 com-
pleted and were included in the QoL and efﬁcacy analyses. Most
patients were Caucasian (78.1%) and the mean age was 38 (±11)
years. Statistically signiﬁcant improvements after four weeks of
tegaserod treatment were observed for overall QoL (19.6%
improvement from baseline) and for all IBS-QoL domains (both
p < 0.001 vs baseline). Overall, symptom relief was reported by
68.7% of patients at Week four (95% CI: 62.0–75.4%). Statis-
tically signiﬁcant improvements were reported for the number of
bowel movements, stool form, straining, sense of incomplete
evacuation, abdominal pain and bloating (all p £ 0.001).
Symptom improvements were observed early (Week one of treat-
ment) and sustained throughout the study. 58.1% of patients
(95% CI 51.4–64.8%) responded to treatment and concurrently
experienced overall QoL improvement. CONCLUSIONS:
Tegaserod six mg b.i.d. signiﬁcantly improves QoL and is efﬁ-
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OBJECTIVES: To evaluate the cost-effectiveness of a diagnostic
technique when no gold standard is available. METHODS:
Capsule endoscopy (CE) is a technique for intraluminal imaging
of the entire small bowel. Sensitivity and speciﬁcity for CE, push
enteroscopy (PE) and other procedures performed prior to diag-
nosis were evaluated from seven controlled clinical trials (n =
184). To evaluate the cost-effectiveness of CE in diagnosing
obscure gastrointestinal bleeding (OGIB) a microsimulation
model was developed. Procedure cost, costs of diagnostic failure
and incremental cost-effectiveness ratios dependent on disease
prevalence are given. Costs due to false negative diagnosis were
examined in cycles with a prevalence range from 10% to 90%.
One way as well as probabilistic sensitivity analysis was per-
formed. Cost data reﬂect the Swiss healthcare payer perspective.
RESULTS: Sensitivity for CE was 89–99% and 27–60% for PE.
Speciﬁcity was 90–99% and 50–70% respectively. Mean future-
costs reach from 7.664€ for cycle 1 to 3.129€ for cycle nine. With
a prevalence >10% CE was the dominant strategy. For a preva-
lence of 50% cost savings are 2240€. CONCLUSIONS: The
model proved to be helpful in the evaluation of CE where gold
standard data were not available. From a health-economic per-
spective the use of CE can be recommended in the work-up of
patients with OGIB. Based on the results of the described method
Switzerland approved reimbursement for CE in patients with
OGIB after negative upper and lower endoscopy.
